SCHEMBL26506594

SCHEMBL26506594

COC(=O)c1ccccc1Oc1nc(Nc2ccc(N3CCNCC3)cc2)ncc1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 1/20 0.56
▸ JAK3 P52333 1/20 0.56
▸ BTK Q06187 1/20 0.56
▸ TNK2 Q07912 1/20 0.56
▸ BRD4 O60885 3/20 0.53
▸ MAPK8 P45983 1/20 0.53
▸ MAPK9 P45984 1/20 0.53
▸ MAPK10 P53779 1/20 0.53
▸ ULK1 O75385 2/20 0.51
▸ PRKAA2 P54646 1/20 0.51
▸ PRKAA1 Q13131 1/20 0.51
▸ ULK2 Q8IYT8 1/20 0.51
▸ CDK4 P11802 5/20 0.49
▸ CCND1 P24385 5/20 0.49
▸ CDK2 P24941 5/20 0.49
▸ CDK1 P06493 3/20 0.49
▸ STAT6 P42226 1/20 0.49
▸ CCNB1 P14635 2/20 0.48
▸ CCNE1 P24864 2/20 0.48
▸ CCNA2 P20248 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26506563 0.92 ULK1 (0.53) LCKJAK3BTKTNK2ULK1
SCHEMBL26506540 0.90 IGF1R (0.56) LCKMAPK8MAPK9MAPK10ULK1
SCHEMBL26506537 0.90 CDK4 (0.60) LCKJAK3BTKBRD4ULK1
SCHEMBL26506589 0.83 ULK1 (0.59) MAPK8ULK1PRKAA2PRKAA1ULK2
SCHEMBL26506579 0.83 ULK1 (0.59) MAPK8ULK1PRKAA2PRKAA1ULK2
SCHEMBL26506551 0.82 ULK1 (0.61) MAPK9MAPK10ULK1PRKAA2PRKAA1
SCHEMBL26506580 0.82 ULK1 (0.58) MAPK8MAPK9ULK1PRKAA2PRKAA1
SCHEMBL26506586 0.80 ULK1 (0.56) JAK3MAPK8MAPK9MAPK10ULK1
SCHEMBL26506581 0.80 ULK1 (0.56) MAPK8ULK1PRKAA2PRKAA1ULK2
SCHEMBL26506572 0.80 ULK1 (0.56) MAPK8ULK1PRKAA2PRKAA1ULK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME Sanford Burnham Prebys Medical Discovery Institute 2023-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135635-A1 INHIBITORS OF ULK1/2 AND METHODS OF USING SAME ULK2, ULK1, ULK3 LCK 1010/4885JAK3 1330/4885BTK 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback